Overview

Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)

Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
0
Participant gender:
All
Summary
To explore the mechanisms of dyspnea relief during exercise in patients with COPD following treatment with tiotropium bromide (Spiriva)
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bromides
Tiotropium Bromide
Criteria
Inclusion criteria: Patients with chronic obstructive pulmonary disease (COPD) with FEV1 <
70% predicted and FRC > 120% predicted, a cigarette smoking history > 20 pack-years, and
moderate to severe chronic dyspnea

Exclusion criteria: patients with a history of asthma, allergic rhinitis or atopy; patients
who participated in a rehabilitation program for COPD within 6 weeks prior to screening